

BROCHURE

Together for Minimizing Risk

Pharmacovigilance Services


The successful development of any therapeutic product depends on numerous factors including the safety and efficacy profile, quality of clinical data, appropriate regulatory strategies, and timely regulatory submissions. Drug development is a long, complex process, which can span 10 to 15 years from the discovery stage through successful completion of all stages of clinical development to authorization. With the key objective of patient safety, the regulators are working to evolve in order to address increasing complexities of product types. As a result, the regulatory requirements are complex and dynamic, adding to the complexity of global end-to-end Pharmacovigilance systems. Biopharmaceutical companies are expected to adopt a proactive pharmacovigilance strategy as they seek market approval for their products. Therefore, appropriate risk mitigation strategies and pharmacovigilance processes should be in place as early as feasible.

Why APCER as a Strategic Partner?


Partnering with a provider who has strong expertise, understanding and adapting to global and regional regulatory requirements can be highly beneficial to ensure safe and effective use of therapeutic products as well as anytime inspection readiness.

As an end-to-end Pharmacovigilance service provider, APCER has the expertise to monitor the regulatory landscape and assess the impact to pharmacovigilance processes to ensure compliance.

Core Pharmacovigilance and Complementary Services



Technology Enablers



Therapeutic and Product Experience

Our expertise extends to every therapeutic area and covers a wide range of products such as Drugs, Vaccines, Biologics, Biosimilars, Medical Devices, Combination products, Advanced Therapeutic Medicinal products (ATMPs) and Cell & Gene therapies (CGTs).

Therapeutic experience across product types

